Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159750 · ClinicalTrials.gov registry record
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
A clinical trial of Migraine and Episodic Migraine, sponsored by Hospital Universitari Vall d'Hebron Research Institute.
- Recruiting
- Registry status
- 700
- Enrollment target
- 20
- Study locations
NCT07159750: Recruiting study of Migraine and Episodic Migraine, sponsored by Hospital Universitari Vall d'Hebron Research Institute.
NCT07159750 is a study of Migraine and Episodic Migraine that is actively recruiting participants, run by Hospital Universitari Vall d'Hebron Research Institute. The registered enrollment target is 700 participants, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07159750, a study of Migraine and Episodic Migraine, is actively recruiting participants, sponsored by Hospital Universitari Vall d'Hebron Research Institute.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Conditions Studied
Interventions
- DRUG CGRP antibody or gepant
Study Locations (20)
Other
- FLENI - Buenos Aires
- Pontificia Universidad Católica de Chile - Santiago
- Neuromedica - Medellín
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno - Rovinj
- Charité Universitätsmedizin Berlin - Berlin
- LMU University Hospital - München
- University of L'Aquila - L’Aquila
- University of Modena and Reggio Emilia - Modena
- National Neurological Institute C. Mondino Foundation - Pavia
- IRCCS San Raffaele - Roma
- Neuroclinic Norway - Lillestrøm
- Wrocław Medical University - Wroclaw
- Hospital Santa Maria Lisbon - Lisbon
Barcelona
- Germans Trias i Pujol Hospital - Badalona
- Vall d'Hebron University Hospital - Barcelona
- Hospital Universitari de Bellvitge - L'Hospitalet de Llobregat
- Fundació Sanitària Mollet - Mollet del Vallès
- Hospital de Viladecans - Viladecans
Florida
- University of Miami, Miller School of Medicine - Miami
Selangor
- Universiti Putra Malaysia - Serdang
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-01 |
What NCT07159750 shows while recruiting
NCT07159750 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (99% higher).
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which CGRP antibody or gepant is the first listed.
NCT07159750 names 20 study sites across 4 states, led by Other, Barcelona, Florida.
Frequently Asked Questions
What is clinical trial NCT07159750 about?
NCT07159750 is a clinical study titled "Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine". The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, a...
What is the current status of trial NCT07159750?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2024-01-02. Estimated completion is 2026-01.
What conditions does trial NCT07159750 study?
This clinical trial studies the following conditions: Migraine, Episodic Migraine, Chronic Migraine, Headache.
What interventions are being tested in trial NCT07159750?
The interventions under investigation include: CGRP antibody or gepant (DRUG).
Who is sponsoring clinical trial NCT07159750?
This trial is sponsored by Hospital Universitari Vall d'Hebron Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159750 being conducted?
This trial has 20 study locations across Florida, Selangor, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07159750's enrollment target sits among peer trials
700 14th of 102 higher than 89 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI